Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know

Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.

Kiplinger

High blood pressure rates in children nearly doubled in 20 years, global review finds

Poor diet, inactivity and obesity believed to have caused hypertension for millions of under-19s around the world

The Guardian - UK

Trump's Visa Crackdown: 'Heavy' Foreign Visitors Told They May Be Barred From The U.S.

A newly revealed State Department cable instructs visa officers to consider chronic conditions — including obesity — when refusing visas as potential 'public charge' cases; lawyers warn of bias and legal uncertainty. Facts, expert views, and what applicants must know.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

US could block obese visitors from entering country under new visa guidance

Obesity is just one of the conditions which could get visitors denied a US visa

Evening Standard

New Trump directive could deny more visas based on applicants' health and finances

A new directive by President Donald Trump’s administration could make it more difficult for foreigners to visit or live in the United States if they have certain medical conditions such as diabetes or obesity or lack the economic resources and assets to support themselves

The Independent UK

Markets exhale as Novo Nordisk withdraws from Metsera bidding war

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.

Euronews

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Obesity is now legally recognised as a chronic disease in Italy – a historic advance for public health in Europe

On October 9 2025, Italy took the unprecedented step of approving a law that recognises obesity as a chronic, progressive, and relapsing disease. The law came into effect on October 25.

The Conversation

The science of weight loss – and why your brain is wired to keep you fat

For decades, we’ve been told that weight loss is a matter of willpower: eat less, move more. But modern science has proven this isn’t actually the case.

The Conversation

Donald Trump Rule: Age, Obesity, Diabetes Trigger US Visa Ban on Public Charge

The Trump administration issued a new directive allowing US visa officers to reject applicants based on obesity, diabetes, and age. The policy flags immigrants as a potential 'public charge.'

International Business Times UK

The nut secret: 14 easy, delicious ways to eat more of these life-changing superfoods

A handful of nuts a day can help manage obesity and reduce your risk of cardiovascular disease, type 2 diabetes and some kinds of cancer. Yet most of us don’t get enough. Here’s a no-fuss guide to getting your 30g a day

The Guardian - UK

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK

Fact check: Fake ‘train attack’ imagery and child obesity stats

Round-up of fact checks from the last week compiled by Full Fact.

Evening Standard

On the same day as his ‘fat jab’ launch, Trump issued new reason to deny visas to foreigners: obesity

The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in benefits

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘Dozy Don’ allegations reappear after president closes eyes during Dr. Oz speech

President photographed appearing to doze during announcement of price cuts for weight loss drugs – which tackle obesity and aid sleep

Benzinga

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

International Business Times UK

TrumpRx News: Why Donald Trump Struck a Deal With Novo Nordisk's Weight Loss Drugs — And What It Says About America's Obesity Problem

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current average retail price of $1,000–$1,350.

Euronews

Childhood obesity reaching ‘alarmingly high’ levels in Europe, WHO report warns

Child obesity rates have stabilised in some countries in recent years – but global health officials said they were still too high.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

The Independent UK

Trump announces plans to slim down cost of popular weight-loss drugs to $149 a month

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan

The Independent UK

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

Benzinga

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.

The Independent UK

This is the exercise you need to combat obesity and diabetes, new study says

It’s estimated that more than 5.8 million people in the UK are living with diabetes, which is an all-time high, according to Diabetes UK

Benzinga

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.